Naturally Supports Lower Intraocular Pressure

Ocular Pressure Defense

Item# HOP10
1 Bottle

illustration of eye showing ocular pressure

Ocular Pressure Defense:

  • With Mirtogenol®—clinically shown to reduce intraocular pressure
  • Improves blood flow and nutrient delivery to your eyes
  • Supports healthy eye tissues, including blood vessels and capillaries
  • Safe to take with cardio medications

Intraocular pressure refers to your eye’s ability to properly drain the fluid that exists between your lens and cornea. Keeping this pressure low is essential to eye health, but until now, there was little help for those with ocular pressure problems. 

Mirtogenol is a proprietary combination of 2 specific, high-quality extracts:

  • Mirtoselect® Bilberry, which contains abundant anthocyanosides and other powerful flavonoids that have been shown in research to strengthen the delicate capillaries of the eyes and increase microcirculation.
  • Pycnogenol® Maritime Pine Bark, cultivated only from the coastal pine forests of France. Clinical studies show that this extract also strengthens capillaries. Plus, it works to lower a peptide that causes blood vessels to constrict, thereby keeping the tiny vessels in your eyes open and enhancing nutrient and oxygen delivery.
    And scientists believe it is this vasodilation action that is critical for lowering intraocular pressure.

Two clinical studies show impressive results with Mirtogenol

Mirtogenol has been the subject of two clinical studies. In one study, 79 subjects using 120 mg per day of Mirtogenol experienced a significant 9 point average reduction in intraocular pressure.

In a second study using 240 mg per day of Mirtogenol, 19 out of 20 people experienced a reduction in intraocular pressure, versus only 1 out of 18 subjects in the control group.

And with just 1 to 2 capsules a day of Ocular Pressure Defense, you get the full researched doses!

Support your eyes inside and out with regular eye exams, a healthy diet, regular exercise, and now with Ocular Pressure Defense, an exact blend of nutrients to promote lower intraocular pressure!

Ingredients & Dosage

Ocular Pressure Defense: 1 capsule gives you...

Mirtogenol®‡ Proprietary Blend
Mirtoselect®♦ Bilberry Extract (fruit),
Pycnogenol® French Maritime Pine Extract (bark)
120 mg

Other ingredients: Microcrystalline cellulose, gelatin, silicon dioxide, magnesium stearate

‡Mirtogenol® is a registered trademark of Horphag Research and Indena and is protected by international and pending patents.
♦Mirtoselect® is a registered trademark of Indena S.p.A.
Pycnogenol® is a registered trademark of Horphag Research Ltd.

Take 1–2 capsules daily.
Note: This product is not recommended for children.

Allergy Information:
This product does not contain any major allergen (soy, milk, wheat, egg, shellfish, fish, peanuts, tree nuts).

Side Effects:
There are no known side effects associated with this product. However, as with any food product, there may be infrequent and highly sensitized reactions associated with this or any other nutritional supplement. If such a reaction occurs, you should consider discontinuing use of this or any product.

This product is not a treatment for glaucoma. If you are lactating, pregnant or planning to become pregnant, consult a health care professional before taking this product. Stop use if allergic reaction occurs.
Keep out of reach of children.

Batch Information

Product Quality

Scientific Support

Researchers divided 38 subjects to either supplementation with 240 mg of Mirtogenol daily, or no treatment at all. Subjects were followed for 6 months. Blood flow in the central retinal artery, ophthalmic artery and posterior ciliary artery all increased in the Mirtogenol group after 3 and 6 months of treatment.1

In a second trial, researchers examined the effect of Mirtogenol (120 mg/day) on intraocular pressure in 79 healthy subjects for 6 months. Similar results were seen with ocular blood flow, with Mirtogenol increasing blood flow.2

1 Steigerwalt RD et al. Mol Vis 2008;14:1288-92.
2 Steigerwalt RD et al. Clin Ophthalmol 2010;4:1-6.